Skip to Main Content
Wexler Boley & Elgersma LLP
  • Our Firm
    • Who We Serve
      • Shareholders
      • Whistleblowers
      • Consumers
      • Businesses
      • Government Entities
    • Our Professionals
    • Working with Wexler Boley & Elgersma LLP
    • Locations
    • News
    • Careers
    • Report Your Concern
    • Testimonials
  • Practice Areas
    • Antitrust Litigation
    • Business & Commercial Litigation
    • Securities & Corporate Governance
    • Healthcare Litigation
    • Consumer Protection
    • Whistle Blower False Claims Litigation
    • Government Representation
    • Employment Litigation
  • Cases
    • Antitrust Litigation Cases
    • Business & Commercial Litigation Cases
    • Consumer Protection Cases
    • Employment Litigation Cases
    • Government Representation Cases
    • Healthcare Litigation Cases
    • Mass Tort Litigation Cases
    • Securities & Corporate Governance Cases
    • Whistle Blower False Claims Cases
  • Investigations
    • Similac Toxic Infant Formula Lawsuit
    • Kid’s Castle Biometric Privacy Lawsuit
    • Contaminated Baby Food Lawsuit
    • Fatal Sportmix Pet Food Recall Class Action Lawsuit
    • Claire’s Data Breach Lawsuit
    • Insurance Denial for Mental Health and Substance Abuse Treatment
    • Perpetual Sales Litigation
    • Railroad Price-Fixing Lawsuit
    • Medicare Advantage Fraud Litigation
    • Biometric Fingerprinting Litigation
  • Blog
  • Contact Us
See all news
1.15.2018

Asacol Antitrust Trial to Begin January 22, 2018

Case Update: The First Circuit stayed the trial set to begin on January 22, 2018 pending the resolution of Defendants’ appeal of the District Court’s class certification decision.

Following the November 9th opinion of the Hon. Judge Denise J. Casper’s denial of summary judgement and certification of the class, the case of In re: Asacol Antitrust Litigation, Case No.: 1:15-cv-12730-DJC will proceed to trial on Monday, January 22nd at 8:45 a.m. EST. The trial will be held at the United States District Court for the District of Massachusetts, 1 Courthouse Way Boston, Massachusetts 02210.

Warner Chilcott, the Allergan subsidiary and manufacturer of Asacol, is accused of using an alleged unlawful anticompetitive “product hop” scheme to prevent a generic version of Asacol 400mg from reaching the market, thus preserving its monopoly profits on a “new” patent-protected drug—Delzicol.

Plaintiffs in this case are represented by Wexler Wallace LLP, Wagstaff & Cartmell LLP, Gustafson Gluek PLLC, and others.

Share

  • Facebook
  • Twitter
  • LinkedIn
Image

311 S. Wacker Drive,
Suite 5450
Chicago, IL 60606
P_312.346.2222
F_312.346.0022

  • Our Firm
  • Practice Areas
  • Cases
  • Investigations
  • Newsroom
  • Blog
  • Contact Us
  • Sitemap
  • Privacy Statement
  • Legal Disclaimer

2022 © Wexler Boley & Elgersma LLP